බර අඩු කරන අනුමත බෙහෙත් | Weight Loss Medicine By Nutritionist Hiroshan Jayaranga

Описание: WHO Approved GLP-1 Receptor Agonists for Obesity | Semaglutide, Liraglutide | Evidence-Based Explanation

In this video, I clearly explain the World Health Organization (WHO) 2024–2025 Obesity Guidelines and how they officially recognize GLP-1 receptor agonists as evidence-based medications for weight loss and long-term obesity management.

According to WHO, medications such as:

🔹 Liraglutide 3 mg (Saxenda)
🔹 Semaglutide 2.4 mg (Wegovy)

are approved as pharmacological treatment options for adults with obesity or overweight with medical complications.
These medications help reduce body weight by:

✓ Reducing appetite
✓ Improving satiety
✓ Decreasing gastric emptying
✓ Reducing caloric intake

In this video, I discuss:

✔ WHO guidelines on obesity treatment
✔ Why GLP-1 RAs are recommended for high-risk patients
✔ Evidence from clinical trials (STEP, SCALE, etc.)
✔ Expected weight loss percentages
✔ Safety profile and monitoring
✔ Who is eligible and who is not
✔ Long-term metabolic benefits

As a Medical Council–registered Nutritionist, I explain all information clearly using research-based evidence for the Sri Lankan audience.

📌 For more medically accurate nutrition and weight-loss content, subscribe to Nutri Info Sri Lanka.

🏮WhatsApp එකෙන් online Consultation එකක් බුක් කරගන්න / Book Online Consultation Over Whatsapp - +947600 50 620

💁 වෙබ් එකෙන් online Consultation එකක් බුක් කරගන්න / Book Online Consultation Over Web - www.nutriinfosl.com

📞 Contact NuTri InFo Assistance Team (Hotline) : +9471 8 620 620

❤️ Be a Member of Nutri Info Family ❤️ (Patreon) - https://patreon.com/NutriInfo?utm_med...

🔔Facebook පිටුව හා එක්වන්න - https://www.facebook.com/profile.php?...
🔔 Instagram - https://www.tiktok.com/@nutriinfosl?l...
🔔Tik Tok - https://www.tiktok.com/@nutriinfosl?_...
🔔Apple Podcast - https://podcasts.apple.com/.../nutri-...
🔔Spotify - https://podcasters.spotify.com/pod/sh...
🔔Podcast In Facebook - https://fb.watch/okKHHLzZEh/
🔔Email - [email protected]